Moderna, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-03-04$57.80 RISE2026-05-01$45.37 PEAK2026-05-08$54.35 65d | -21.5% 58d | Missed | Missed | — | — | +19.8% 7d | Missed |
DROP2025-07-23$34.67 RISE2025-11-20$22.36 PEAK2026-01-22$51.87 183d | -35.5% 120d | Missed | Missed | — | — | +132.0% 63d | Missed |
DROP2025-07-23$34.67 RISE2025-09-12$23.51 PEAK2025-10-03$28.49 72d | -32.2% 51d | Missed | Missed | — | — | +21.2% 21d | Missed |
DROP2025-03-10$35.96 RISE2025-06-18$25.40 PEAK2025-07-23$34.67 135d | -29.4% 100d | Missed | Missed | — | — | +36.5% 35d | Missed |
DROP2025-01-07$47.53 RISE2025-05-15$23.65 PEAK2025-07-23$34.67 197d | -50.2% 128d | Missed | Missed | — | — | +46.6% 69d | Missed |
DROP2024-07-16$125.14 RISE2024-11-15$36.85 PEAK2025-01-07$47.53 175d | -70.6% 122d | Missed | Missed | — | — | +29.0% 53d | Missed |
DROP2024-01-08$115.44 RISE2024-02-13$85.37 PEAK2024-05-02$125.59 115d | -26.0% 36d | 2024-01-29 $104.84 | 2024-02-23 $96.46 | 76Quality on Sale | 37Watch | +47.1% 79d | -8.0% Held 25d |
DROP2023-07-13$126.61 RISE2023-11-09$69.51 PEAK2024-01-08$115.44 179d | -45.1% 119d | 2023-08-07 $101.20 | 2024-01-08 $115.44 | 66Quality on Sale | 75Quality on Sale | +66.1% 60d | +14.1% Held 154d |
DROP2023-04-13$160.53 RISE2023-08-15$96.41 PEAK2023-08-30$116.62 139d | -39.9% 124d | 2023-08-07 $101.20 | 2023-08-30 $116.62 | 66Quality on Sale | 61Quality on Sale | +21.0% 15d | +15.2% Held 23d |
DROP2022-12-21$210.04 RISE2023-03-01$135.66 PEAK2023-04-13$160.53 113d | -35.4% 70d | Missed | Missed | — | — | +18.3% 43d | Missed |
DROP2022-08-04$194.18 RISE2022-09-29$118.07 PEAK2022-12-21$210.04 139d | -39.2% 56d | Missed | Missed | — | — | +77.9% 83d | Missed |
DROP2022-03-22$186.72 RISE2022-06-13$117.13 PEAK2022-08-04$194.18 135d | -37.3% 83d | Missed | Missed | — | — | +65.8% 52d | Missed |
DROP2021-12-31$253.98 RISE2022-05-11$123.43 PEAK2022-08-04$194.18 216d | -51.4% 131d | Missed | Missed | — | — | +57.3% 85d | Missed |
DROP2021-11-29$368.51 RISE2022-03-07$126.46 PEAK2022-03-22$186.72 113d | -65.7% 98d | Missed | Missed | — | — | +47.7% 15d | Missed |
DROP2021-08-09$484.47 RISE2021-11-11$225.82 PEAK2021-11-29$368.51 112d | -53.4% 94d | Missed | Missed | — | — | +63.2% 18d | Missed |
1–15 / 22 1 / 2 | |||||||
Anterix enables secure wireless communications for utilities and critical infrastructure through its nationwide 900 MHz spectrum portfolio.
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.
BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Dai moved off the sidelines Wednesday as he upgraded BioNTech stock to Buy from Neutral with a $135 price target, up from $117.
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
In May 2026, Roivant Sciences reported fourth-quarter 2026 results showing sales of US$2.52 million, a swing to quarterly net income of US$302.99 million, and full-year 2026 sales of US$8.26 million alongside a wider annual net loss of US$299.77 million. The earnings were heavily influenced by a US$770.2 million litigation settlement gain linked to Genevant’s US$2.25 billion global patent settlement with Moderna, highlighting how non-operating items and asset monetization can meaningfully...
In May 2026, Roivant Sciences reported fourth-quarter 2026 results showing sales of US$2.52 million, a swing to quarterly net income of US$302.99 million, and full-year 2026 sales of US$8.26 million alongside a wider annual net loss of US$299.77 million. The earnings were heavily influenced by a US$770.2 million litigation settlement gain linked to Genevant’s US$2.25 billion global patent settlement with Moderna, highlighting how non-operating items and asset monetization can meaningfully...
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US federal district courts, aligning with recent Delaware law changes, while the FDA set a June 18 advisory panel review for the company’s mRNA-based seasonal flu vaccine after an earlier filing setback. Together with ongoing insider share sales under a preset trading plan and fresh real-world data on its pediatric COVID-19 vaccine effectiveness, these developments sharpen...
On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US federal district courts, aligning with recent Delaware law changes, while the FDA set a June 18 advisory panel review for the company’s mRNA-based seasonal flu vaccine after an earlier filing setback. Together with ongoing insider share sales under a preset trading plan and fresh real-world data on its pediatric COVID-19 vaccine effectiveness, these developments sharpen...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 7.8% has lagged the S&P 500’s 13.2% climb.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 7.8% has lagged the S&P 500’s 13.2% climb.
The Food and Drug Administration is eyeing a meeting on June 18 to discuss mRNA-1010.
The Food and Drug Administration is eyeing a meeting on June 18 to discuss mRNA-1010.
FDA to review Moderna's experimental mRNA flu shot on June 18 as the agency signals a more transparent approval process.
Moderna (NASDAQ:MRNA) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story deserves a closer look. The Moderna Story Has Not Changed Strip away the bounce and the fundamentals tell the same story long-term investors have heard for three ... Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now
Moderna (NASDAQ:MRNA) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story deserves a closer look. The Moderna Story Has Not Changed Strip away the bounce and the fundamentals tell the same story long-term investors have heard for three ... Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now
https://www.bloomberg.com/news/articles/2026-05-21/fda-plans-rare-advisory-hearing-to-debate-moderna-s-flu-shot
The Food and Drug Administration is rudderless. Its commissioner, Marty Makary, is gone. The rise of the Make America Healthy Again movement, with its vaccine skepticism and adversarial stance toward drugmakers, has hung over biotech since Robert F. Kennedy Jr. took over at the Department of Health and Human Services.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| MRNA | +4.01% | -10.70% | +60.02% | +77.67% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +1.04% | -4.99% | +63.46% | +64.98% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 45.67M | $2.32B | 0.12% | Added+62.9% | 2026-03-31 |
| StateStreet | passive | 14.86M | $754.96M | 0.03% | Trimmed-9.2% | 2026-03-31 |
| TwoSigma | quant | 9.09M | $461.59M | 0.37% | Added+23.8% | 2026-03-31 |
| Wellington | fundamental | 2.36M | $119.77M | 0.02% | Added+2730.4% | 2026-03-31 |
| RenTech | quant | 881.2K | $44.76M | 0.07% | Added+55.0% | 2026-03-31 |
| DEShaw | quant | 666.5K | $33.86M | 0.02% | Trimmed-87.1% | 2026-03-31 |
| Citadel | multi-strat | 197.8K | $10.05M | 0.01% | New | 2026-03-31 |
| Bridgewater | macro | 74.8K | $3.80M | 0.02% | Added+392.9% | 2026-03-31 |
| TRowePrice | fundamental | 738.6K | $37.52K | 0.00% | Added+49.5% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-29 | Hoge Stephen | President | M Option exercise(deriv) | 610 | — | +$0 |
| 2026-05-29 | Hoge Stephen | President | M Option exercise(deriv) | 1,437 | — | +$0 |
| 2026-05-29 | Hoge Stephen | President | F Tax withholding | 295 | $47.61 | −$14.0K |
| 2026-05-29 | Hoge Stephen | President | M Option exercise | 610 | — | — |
| 2026-05-29 | Hoge Stephen | President | F Tax withholding | 695 | $47.03 | −$32.7K |
| 2026-05-29 | Hoge Stephen | President | M Option exercise | 1,437 | — | — |
| 2026-05-29 | Klinger Shannon Thyme | Chief Legal Officer | M Option exercise(deriv) | 328 | — | +$0 |
| 2026-05-29 | Klinger Shannon Thyme | Chief Legal Officer | M Option exercise(deriv) | 773 | — | +$0 |
| 2026-05-29 | Klinger Shannon Thyme | Chief Legal Officer | F Tax withholding | 159 | $47.61 | −$7.6K |
| 2026-05-29 | Klinger Shannon Thyme | Chief Legal Officer | M Option exercise | 328 | — | — |
| 2026-05-29 | Klinger Shannon Thyme | Chief Legal Officer | F Tax withholding | 374 | $47.03 | −$17.6K |
| 2026-05-29 | Klinger Shannon Thyme | Chief Legal Officer | M Option exercise | 773 | — | — |
| 2026-05-29 | Mock James M | Chief Financial Officer | M Option exercise(deriv) | 328 | — | +$0 |
| 2026-05-29 | Mock James M | Chief Financial Officer | M Option exercise(deriv) | 773 | — | +$0 |
| 2026-05-29 | Mock James M | Chief Financial Officer | F Tax withholding | 159 | $47.61 | −$7.6K |
| 2026-05-29 | Mock James M | Chief Financial Officer | M Option exercise | 328 | — | — |
| 2026-05-29 | Mock James M | Chief Financial Officer | F Tax withholding | 374 | $47.03 | −$17.6K |
| 2026-05-29 | Mock James M | Chief Financial Officer | M Option exercise | 773 | — | — |
| 2026-05-22 | AFEYAN NOUBAR | Director | M Option exercise(deriv) | 9,263 | — | +$0 |
| 2026-05-22 | AFEYAN NOUBAR | Director | S Open-market sale | 9,263 | $46.84 | −$433.9K |
| 2026-05-22 | AFEYAN NOUBAR | Director | M Option exercise | 9,263 | $19.15 | +$177.4K |
| 2026-05-18 | Hoge Stephen | President | M Option exercise(deriv) | 16,110 | — | +$0 |
| 2026-05-18 | Hoge Stephen | President | M Option exercise(deriv) | 37,226 | — | +$0 |
| 2026-05-18 | Hoge Stephen | President | S Open-market sale | 53,336 | $48.40 | −$2.58M |
| 2026-05-18 | Hoge Stephen | President | M Option exercise | 16,110 | $19.15 | +$308.5K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-31upcoming | -2.09 | — | — |
| 2026-04-30 | -3.88 | -3.40 | +12.37% |
| 2026-02-13 | -2.60 | -2.11 | +18.88% |
| 2025-11-06 | -2.18 | -0.51 | +76.60% |
| 2025-08-01 | -2.97 | -2.13 | +28.28% |
| 2025-05-01 | -3.18 | -2.52 | +20.69% |
| 2025-02-14 | -2.76 | -2.91 | -5.44% |
| 2024-11-07 | -1.93 | 0.03 | +101.55% |
| 2024-08-01 | -3.35 | -3.33 | +0.65% |
| 2024-05-02 | -3.57 | -3.07 | +14.06% |
| 2024-02-22 | -0.98 | 0.55 | +156.29% |
| 2023-11-02 | -1.98 | -9.53 | -381.38% |
| 2023-08-03 | -4.10 | -3.62 | +11.66% |
| 2023-05-04 | -1.74 | 0.19 | +110.90% |
| 2023-02-23 | 4.60 | 3.61 | -21.50% |
| 2022-11-03 | 3.19 | 2.53 | -20.57% |